ENTRY       D12207                      Drug
NAME        Pneumococcal 20-valent conjugate vaccine;
            Prevnar 20 (TN);
            Apexxnar (TN)
PRODUCT     PREVNAR 20 (A-S Medication Solutions)
            PREVNAR 20 (Wyeth Pharmaceutical Division of Wyeth Holdings LLC)
REMARK      ATC code: J07AL02
            Product: D12207<US>
EFFICACY    Active immunization (pneumococcal)
  DISEASE   Prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F [DS:H01321]
COMMENT     Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J07 VACCINES
               J07A BACTERIAL VACCINES
                J07AL Pneumococcal vaccines
                 J07AL02 Pneumococcus, purified polysaccharides antigen conjugated
                  D12207  Pneumococcal 20-valent conjugate vaccine &lt;US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Vaccines
               Pneumococcal
                Pneumococcal Conjugate Vaccine 20-valent (PCV20), Polysaccharide CRM197 Conjugate, Adjuvant, PF
                 D12207  Pneumococcal 20-valent conjugate vaccine
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12207
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D12207
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12207
///
